Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

, multi-center, randomized, single-blind, controlled clinical trial comparing XIENCE V to TAXUS in 300 patients (223 XIENCE V patients, 77 TAXUS patients) with either one or two de novo native coronary artery lesions. Patients from Europe, India and New Zealand were enrolled in the trial between July 5, 2005, and Nov.15, 2005.

The primary endpoint of the SPIRIT II trial was in-stent late loss at six months, wherein XIENCE V demonstrated superiority to TAXUS with a statistically significant 69 percent reduction in late loss (mean, 0.11 mm for XIENCE V vs. 0.36 mm for TAXUS). In-stent late loss is a measure of vessel re-narrowing.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure.

XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation (NYSE: ... the annual EuroPCR Scientific Program May 21-24 in ... to present a particularly rich and diversified set of ... Dawkins , M.D., global chief medical officer, Boston ... be presented, including the NG PROMUS trial, which evaluated ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
(Date:5/16/2013)... and SYDNEY , May 16, 2013 /PRNewswire/ ... HIN), a leading innovator of less invasive, miniaturized circulatory support ... today announced that CEO Doug Godshall ... Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  ... Sheraton New York Hotel. A live webcast of ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... biotechnology company,developing clinical stage treatments for cancer and ... from its Phase II,clinical trial of OncoVEX GM-CSF, ... at the 2008 Annual Meeting of the American,Society ... Clinical Trial Details, Phase II Trial Design: ...
... May 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, ... trials of VELCADE based therapies that showed consistently ... diagnosed multiple,myeloma (MM). CR is one of the ... selected for oral presentation at the American Society,of ...
Cached Medicine Technology:BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 6Webs.com ... The simple to read reviews and comprehensive comparisons make ... impartial home security reviews. 6Webs.com just recently finished conducting ... system providers. , Tim Smythe from 6Webs.com reports, "There ... systems due to their ease of use, expandability and ...
(Date:5/18/2013)... Mexico, DF (PRWEB) May 18, 2013 ... by leading ayurvedic education institution in the West. Program ... Learning education. , Ayurveda is a healing modality practiced ... Ayurvedica ), it is considered that health begins when ... a profound understanding of their individual needs. Ayurveda aims ...
(Date:5/18/2013)... IL (PRWEB) May 18, 2013 The ... Oregon Gov. John A. Kitzhaber, M.D., (D) to sign ... law by prohibiting minors under the age of 18 ... would become the third state in the nation to ... have enacted similar indoor tanning bans for minors. Nationwide, ...
(Date:5/18/2013)... Ohio (PRWEB) May 18, 2013 ... Annual Conference, on May 17-22 in Austin, TX ... gather for educational and networking opportunities. , ... brushes, flexible scope repair capabilities and ... with valuable educational information on proper instrument care ...
(Date:5/18/2013)... John Ravera, D.D.S., a Newport Beach ... new member to his dental team, Courtney Marino. , Marino ... for over 10 years. She received her degree from West ... a member of Sigma Pi Alpha, a national honor society ... with patients of all ages, helping them understand the importance ...
Breaking Medicine News(10 mins):Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2
... babies for the presence of a common infection was approved ... streptococcus// is a common infection that is passed from mother ... or even death. ,Although all women are tested ... leave some babies at risk for contracting an infection from ...
... certain premature babies to inhale small amounts of nitric ... bronchopulmonary dysplasia, according// to the results of two studies ... born with this condition each year in the United ... are too immature to mix inhaled air properly with ...
... considering becoming pregnant could prevent preeclampsia if they started ... following it up// during the first three months of ... blood pressure shoots up dangerously and could prove lethal ... of Pittsburgh say that this condition could be avoided ...
... the cornerstones of managing type 2 diabetes. But few ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
... of Medicine, University of California, Los Angels and Valencia, ... developed an alternative to the conventional epilepsy treatment. ... study and the clinical trails show that it has ... nerve that prevents seizures is stimulated to inhibit epilepsy. ...
... by Linda Chaudron, M.D., an assistant professor of psychiatry, pediatrics ... is a disorder which is fast rising among new mothers. ... screened for a period of 12 months after childbirth. Such ... as the symptoms, develop throughout the year. Only if ...
Cached Medicine News:Health News:FDA Approves New Test For Screening Infection In Babies 2Health News:FDA Approves New Test For Screening Infection In Babies 3Health News:Nitric Oxide Could Benefit Premature Babies 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 3Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Alternative to the Conventional Seizure Treatment 2Health News:Early Diagnosis of Postpartum Depression Is Very Essential Among New Mothers 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: